Abstract
Ten patients with Alzheimer's disease were treated with intravenous infusion of physostigmine for 2 h. The acute effects on cognitive function, regional cerebral blood flow, and EEG were compared to placebo (isotonic glucose) using a double-blind cross-over design. Physostigmine causes a limited improvement of psychomotor performance and EEG and an increase of blood flow in the most severely affected cortical areas, predominantly in an early phase of Alzheimer's disease.
Similar content being viewed by others
References
Bowen DM, Smith CB, White P, Davison AN (1976) Neurotrans-mitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophics. Brain 99:459–496
Bowen DM, Spillane JA, Curzon G, Meier-Ruge W, White P, Goodhardt MJ, Iwangoff P, Davison AN (1979) Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet II:11–14
Brun A, Gustafson L (1976) Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study. Arch Psychiatr Nervenkr 223:15–33
Brun A, Gustafson L (1978) Limbic lobe involvement in presenile dementia. Arch Psychiatr Nervenkr 226:79–93
Brun A, Englund E (1981) Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 5:549–564
Catagirone C, Gainotti G, Masullo C (1982) Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 16:247–249
Caltagirone C, Albanese A, Gainotti G, Masullo C (1983) Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimer's presenile dementia. Int J Neurosci 18:143–148
Christie JE, Shering A, Ferguson J, Glen AIM (1981) Physostigmine and arecholine: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138:46–50
Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1403
Davies P, Verth AH (1978) Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains. Brain Res 138:385–392
Davis KL, Mohs RC (1982) Enhancment of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 139(11):1421–1424
Frackowiak RSJ, Pozzilli C, Legg NJ, du Boulay GH, Marschall J, Lenzi GL, Jones T (1981) Regional cerebral oxygen supply and utilization in dementia: a clinical and physiological study with oxygen-15 and positron tomography. Brain 104:753–778
Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE (1983) Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with (18F) fluorodeoxyglucose. J Comput Assist Tomogr 7(4):590–598
Gustafson L, Risberg J (1979) Regional cerebral blood flow measurements by the 133-Xe inhalation technique in differential diagnosis of dementia. Acta Neurol Scand [Suppl 72] 60:546–547
Gustafson L, Nilsson L (1982) Differential diagnosis of presenile dementia on clinical grounds. Acta Psychiatr Scand 65:194–209
Gustafson L, Risberg J, Johanson M, Brun A (1984) Evaluation of organic dementia by regional cerebral blood flow measurements and clinical and psychometric methods. Monogr Neural Sci 11:111–11
Hachinski VC, Iliff LD, Zilhka E, du Boulay GH, McAllister VL, Marshall J, Ross Russel RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637
Hagberg B (1979) Comments on physostigmine assessment in dementia with early onset with special reference to Alzheimer's disease. Presented at Colloquium on Alzheimer's disease. Early recognition of potentially reversible deficits. Edinburgh
Hagberg B, Ingvar DH (1976) Cognitive reduction in presenile dementia related to regional abnormalities of the cerebral blood flow. Br J Psychiatry 128:209–222
Karczmar AG (1977) Exploitable aspects of central cholinergic functions particularly with respect to the EEG, motor, analgetic, and mental functions. In: Jenden D (ed) Cholinergic mechanisms and psychopharmacology. Plenum, New York, pp 679–708
Kuhl DE, Metter EJ, Riege WH, Hawkins RA, Mazziotta JC, Phelps ME, Kling AS (1983) Local cerebral glucose utilization in elderly patients with depression, multiple infarct dementia, and Alzheimer's disease. J Cereb Blood Flow Metab 3 [Suppl 1] 3:494–495
Muramoto O, Sugishita M, Ando K (1984) Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 47:485–491
Obrist WD, Thompson HK, Wang HS, Wilkinson WE (1975) Regional cerebral blood flow estimated by 133-xenon inhalation. Stroke 6:245–256
Perry EK (1986) The cholinergic system in old age and Alzheimer's disease. Age Ageing 9:1–8
Perry EK, Perry RH, Blessed G, Tomlinson BE (1977) Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 189
Pfefferbaum A, Davis KL, Coulter CL, Mohs RC, Tinklenberg JR, Kopell BS (1979) EEG effect of physostigmine and choline chloride in humans. Psychopharmacologia 62:225–233
Risberg J (1980) Regional cerebral blood flow measurements by 133-Xe inhalation: Methodology and applications in neuropsychology and psychiatry. Brain Lang 9:9–34
Rossor MN, Svendsen C, Hunt SP, Mountjoy CQ, Roth M, Iversen LL (1982) The substantia innominata in Alzheimer's disease: A histochemical and biochemical study of cholinergic marker enzymes. Neurosci Lett 28:217–222
Sitaram M, Wyatt RJ, Dawson S, Gillin JC (1976) REM sleep induction by physostigmine during sleep. Science 191:1281–1282
Thal LJ, Fuld PA, Masur DM, Sharpless NS (1983) Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 13:491–496
White P, Goodhardt MJ, Keet JK, Hiley CR, Carrasio LH, Williams IEI (1977) Neocortical cholinergic neurons in elderly people. Lancet 668–671
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gustafson, L., Edvinsson, L., Dahlgren, N. et al. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology 93, 31–35 (1987). https://doi.org/10.1007/BF02439583
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02439583